The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Acceptable changes in quality attributes of glycosylated biopharmaceuticals
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G., & Tak, P. P. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.10.001 · Cited by 1,628
Mechanisms of killing by anti-CD20 monoclonal antibodies
Glennie, M. J., French, R. R., Cragg, M. S., & Taylor, R. P. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.06.151 · Cited by 515
Development and characterization of novel erythropoiesis stimulating protein (NESP)
Egrie, J. C., & Browne, J. K. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1746 · Cited by 510
Egrie, J. C., Dwyer, E., Browne, J. K., Hitz, A., & Lykos, M. A. (2003) · Experimental Hematology · doi:10.1016/s0301-472x(03)00006-7 · Cited by 421
Characterizing biological products and assessing comparability following manufacturing changes
Chirino, A. J., & Mire-Sluis, A. (2004) · Nature Biotechnology · doi:10.1038/nbt1030 · Cited by 364
Development and characterization of novel erythropoiesis stimulating protein (NESP)
Egrie, J. C., & Browne, J. K. (2001) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/16.suppl_3.3 · Cited by 338
Dick, L. W., Kim, C., Qiu, D., et al. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.21260 · Cited by 126
Antes, B., Amon, S., Rizzi, A. M., Wiederkum, S., Kainer, M., Szolar, O. H. J., Fido, M., Kircheis, R., & Nechansky, A. (2007) · Journal of Chromatography B · doi:10.1016/j.jchromb.2007.01.024 · Cited by 86
Understanding and circumventing resistance to anticancer monoclonal antibodies
Reslan, L., Dalle, S., & Dumontet, C. (2009) · mAbs · doi:10.4161/mabs.1.3.8292 · Cited by 60
Cited by
Liu, L. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24444 · Cited by 428
Proposal for a new nomenclature of disease-modifying antirheumatic drugs
Smolen, J. S., van der Heijde, D., Machold, K. P., Aletaha, D., & Landewé, R. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204317 · Cited by 256
In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity
Thomann, M., Schlothauer, T., Dashivets, T., Malik, S., Avenal, C., Bulau, P., Rüger, P., & Reusch, D. (2015) · PLOS ONE · doi:10.1371/journal.pone.0134949 · Cited by 220
Glycan analysis of therapeutic glycoproteins
Zhang, L., Luo, S., & Zhang, B. (2016) · mAbs · doi:10.1080/19420862.2015.1117719 · Cited by 207
The State of the Art in the Development of Biosimilars
McCamish, M., & Woollett, G. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.343 · Cited by 160
Metadata
- Authors
- Schiestl, M., Stangler, T., Torella, C., Čepeljnik, T., Toll, H., & Grau, R.
- Venue
- Nature Biotechnology
- Published
- 2011-04
- Volume
- 29
- Issue
- 4
- Pages
- 310-312
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2023749561
- Cited by
- 473
- References
- 10
- FWCI
- 13.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Acceptable changes in quality attributes of glycosylated biopharmaceuticals. https://app.cochat.ai/papers/10.1038/nbt.1839
- The paper
- Schiestl, M., Stangler, T., Torella, C., Čepeljnik, T., Toll, H., & Grau, R. (2011). Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nature Biotechnology. https://doi.org/10.1038/nbt.1839
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
